Sean Bickerton, MD, PhD
Assistant Professor of Pediatrics (Hospital Medicine)About
Research
Publications
2025
CD2-targeted nanoparticles encapsulating IL-2 induce tolerogenic Tregs and TGF-β-producing NK cells that stabilize Tregs for long-term therapeutic efficacy in immune-mediated disorders
Horwitz D, Kim D, Kang C, Brion K, Bickerton S, La Cava A. CD2-targeted nanoparticles encapsulating IL-2 induce tolerogenic Tregs and TGF-β-producing NK cells that stabilize Tregs for long-term therapeutic efficacy in immune-mediated disorders. Frontiers In Immunology 2025, 16: 1587237. PMID: 40799646, PMCID: PMC12339487, DOI: 10.3389/fimmu.2025.1587237.Peer-Reviewed Original ResearchConceptsNK cellsIL-2TGF-bFatal graft-versus-host diseasePoly(lactic-co-glycolic) acidGraft-versus-host diseaseLong-term immune toleranceLong-term therapeutic efficacyNK cell depletionInduction of TregsT regulatory cellsImmune-mediated disordersTreatment of miceAnti-CD2 antibodiesImmune-mediated diseasesTGF-b signalingCell-targeted approachesTolerogenic cellsCD4+Immune toleranceTolerogenic responsesTregsTherapeutic efficacyCell depletionImmunogenic response
2024
Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen
Horwitz D, Wang J, Kim D, Kang C, Brion K, Bickerton S, La Cava A. Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen. Frontiers In Immunology 2024, 15: 1429335. PMID: 39131162, PMCID: PMC11310063, DOI: 10.3389/fimmu.2024.1429335.Peer-Reviewed Original ResearchNP-treated miceT regulatory cellsMixed lymphocyte reactionDendritic cellsTolerogenic nanoparticlesAllogeneic cellsIL-2CD8+ T regulatory cellsGraft-versus-host diseaseAlloantigen-specific TregInhibition of mixed lymphocyte reactionTGF-bRecipient dendritic cellsGraft-versus-hostTolerogenic dendritic cellsResponse to alloantigensTolerance to alloantigensStrains of miceAlloantigen immunizationDecreased alloreactivityTolerogenic phenotypeCD4+Allogeneic splenocytesAllograft rejectionImmune suppression
Clinical Care
Overview
Sean Bickerton, MD, PhD, is a pediatrician who specializes in pediatric critical care medicine. He focuses on diagnosing and treating children with severe and life-threatening conditions. He uses a variety of approaches to providing advanced and comprehensive care to hospitalized children.
As an assistant professor of pediatrics at Yale School of Medicine, Dr. Bickerton conducts research on developing new therapies using nanoparticles to treat autoimmune diseases. His goal is to improve outcomes for young patients with challenging immune-related conditions.
Dr. Bickerton received his medical degree from Yale School of Medicine, where he also earned his doctorate in biomedical engineering. He completed his residency in pediatrics at Yale New Haven Children’s Hospital.
Clinical Specialties
News
Get In Touch
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.